Effectiveness of Anti-Psychotic in GPs Setting

SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00543088

Acronym

Serenity

Enrollment

250

Registered

2007-10-12

Start date

2007-01-31

Completion date

2008-06-30

Last updated

2009-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Schizophrenia

Keywords

Schizophrenia, Bipolar Disorder, manic episode, atypical antipsychotic, Schizophrenia or Bipolar Disorder (currently in a manic episode)

Brief summary

Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with Schizophrenia or Bipolar Disorder (currently in a manic episode)

Design outcomes

Primary

Measure	Time frame
to evaluate the patient's functioning, by measuring the Quality of Life. Quality of Life will be assessed by the Q-LES-Q-16 (PRO).	—

Secondary

Measure	Time frame
The clinical efficacy & tolerability of atypical antipsychotics as assessed by the Clinical Global Impression(CGI) & Patient Global Impression of Change(PGIC)scores.	—
The wellbeing of the patients taking atypical antipsychotics as assessed by the Sheehan Disability Scale(SDS)	—

Countries

Belgium

Outcome results